Designed improvement to T-cell immunotherapy by multidimensional single cell profiling

J Immunother Cancer. 2021 Mar;9(3):e001877. doi: 10.1136/jitc-2020-001877.

Abstract

Background: Adoptive cell therapy based on the infusion of chimeric antigen receptor (CAR) T cells has shown remarkable efficacy for the treatment of hematologic malignancies. The primary mechanism of action of these infused T cells is the direct killing of tumor cells expressing the cognate antigen. However, understanding why only some T cells are capable of killing, and identifying mechanisms that can improve killing has remained elusive.

Methods: To identify molecular and cellular mechanisms that can improve T-cell killing, we utilized integrated high-throughput single-cell functional profiling by microscopy, followed by robotic retrieval and transcriptional profiling.

Results: With the aid of mathematical modeling we demonstrate that non-killer CAR T cells comprise a heterogeneous population that arise from failure in each of the discrete steps leading to the killing. Differential transcriptional single-cell profiling of killers and non-killers identified CD137 as an inducible costimulatory molecule upregulated on killer T cells. Our single-cell profiling results directly demonstrate that inducible CD137 is feature of killer (and serial killer) T cells and this marks a different subset compared with the CD107apos (degranulating) subset of CAR T cells. Ligation of the induced CD137 with CD137 ligand (CD137L) leads to younger CD19 CAR T cells with sustained killing and lower exhaustion. We genetically modified CAR T cells to co-express CD137L, in trans, and this lead to a profound improvement in anti-tumor efficacy in leukemia and refractory ovarian cancer models in mice.

Conclusions: Broadly, our results illustrate that while non-killer T cells are reflective of population heterogeneity, integrated single-cell profiling can enable identification of mechanisms that can enhance the function/proliferation of killer T cells leading to direct anti-tumor benefit.

Keywords: CD8-positive T-lymphocytes; adoptive; cell engineering; immunologic techniques; immunotherapy.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Video-Audio Media

MeSH terms

  • 4-1BB Ligand / genetics*
  • 4-1BB Ligand / metabolism
  • Animals
  • Cytotoxicity, Immunologic / genetics
  • Female
  • Gene Expression Profiling*
  • Hepatitis A Virus Cellular Receptor 2 / genetics
  • Hepatitis A Virus Cellular Receptor 2 / metabolism
  • Humans
  • Immunophenotyping
  • Immunotherapy, Adoptive*
  • K562 Cells
  • Leukemia / genetics
  • Leukemia / immunology
  • Leukemia / metabolism
  • Leukemia / therapy*
  • Mice
  • Mice, Inbred NOD
  • Mice, SCID
  • Ovarian Neoplasms / genetics
  • Ovarian Neoplasms / immunology
  • Ovarian Neoplasms / metabolism
  • Ovarian Neoplasms / therapy*
  • Phenotype
  • Receptors, Chimeric Antigen / genetics*
  • Receptors, Chimeric Antigen / metabolism
  • Single-Cell Analysis*
  • T-Lymphocytes / immunology
  • T-Lymphocytes / metabolism
  • T-Lymphocytes / transplantation*
  • Transcriptome*
  • Xenograft Model Antitumor Assays

Substances

  • 4-1BB Ligand
  • HAVCR2 protein, human
  • Hepatitis A Virus Cellular Receptor 2
  • Receptors, Chimeric Antigen
  • TNFSF9 protein, human